ArticleJournal of the neurological sciences2015
Tumefactive demyelinating lesions as a first clinical event: Clinical, imaging, and follow-up observations.
Article in Journal of the neurological sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 51 citations in OpenAlex.
- Non-Syndromic Tumefactive Demyelinating Lesions in the Pediatric Population: Four Case Reports and Review of the Literature.Annals of the Child Neurology Society · 2026Article
- Cerebral tumefactive demyelinating lesions: clinical spectrum, long-term outcomes, and treatment.Acta neurologica Belgica · 2026Article
- Subgroup analysis of tumefactive demyelinating lesions: clinical, imaging features and outcomes.BMJ neurology open · 2025Article
- Long-term outcomes of ADEM-like and tumefactive presentations of CNS demyelination: a case-comparison analysis.Journal of neurology · 2024Article
- Tumefactive demyelinating lesions: a retrospective cohort study in Thailand.Scientific reports · 2024Article
- Clinical spectrum and prognosis of pathologically confirmed atypical tumefactive demyelinating lesions.Scientific reports · 2023Article
- Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.Neurology · 2023Article
- Population-based incidence and clinico-radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States.European journal of neurology · 2022Article
- Central nervous system tumefactive demyelinating lesions: Risk factors of relapse and follow-up observations.Frontiers in immunology · 2022Article
- Tumefactive multiple sclerosis versus high grade glioma: A diagnostic dilemma.Surgical neurology international · 2022Article
- Tumefactive multiple sclerosis versus high-grade glioma: A diagnostic dilemma.Surgical neurology international · 2021Article
- Neuroimaging features of tumefactive demyelinating lesions: A rare case report.European journal of radiology open · 2020Article
- Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions.Journal of neurology · 2019Article
- Progression of tumefactive demyelinating lesion in a child demonstrated with MRI.Radiology case reports · 2018Article
- Pattern Recognition of the Multiple Sclerosis Syndrome.Brain sciences · 2017Review
- Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.Journal of the neurological sciences · 2017Article
- Chinese Guidelines for the Diagnosis and Management of Tumefactive Demyelinating Lesions of Central Nervous System.Chinese medical journal · 2017Article
- Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis.Internal medicine (Tokyo, Japan) · 2017Article
- Reversible disconnection syndrome in a case of acute tumefactive demyelinating lesion: a PET study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2016Article
- Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumefactive demyelinating lesions (TDLs) are associated with a variety of demyelinating diseases in the central nervous system (CNS). However, there are no current guidelines describing how to classify and treat patients with this rare phenotype. Thus, the present study aimed to determine the long-term evolution and disease course of patients initially presenting with TDLs and to describe their clinical and radiographic characteristics.
methodsFrom the National Cancer Center registry of inflammatory diseases of the CNS, 31 patients initially presenting with TDLs with follow-up for at least 12 months were enrolled and their demographic, clinical, and radiographic characteristics were evaluated.
resultsThe median follow-up duration was 37.6 months, during which time 11 patients were diagnosed with neuromyelitis optica spectrum disorder (NMOSD), seven with multiple sclerosis (MS), and 11 remained idiopathic; six did not experience any further clinical events (isolated demyelinating syndrome), and five patients experienced recurrent demyelinating events that were not consistent with either MS or NMOSD. Of the remaining two patients, one was diagnosed with hyperthyroidism-associated demyelination and one with tacrolimus-induced demyelination.
conclusionsThe majority of TDLs evolve into MS or NMOSD. However, despite extensive diagnostic work-ups and long-term follow-ups, the etiology of TDLs was unknown for some patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.